UBS Group started coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX – Free Report) in a research report report published on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $45.00 price target on the stock.
First Tracks Biotherapeutics Price Performance
Shares of First Tracks Biotherapeutics stock opened at $19.00 on Tuesday. First Tracks Biotherapeutics has a 1 year low of $14.79 and a 1 year high of $26.80.
Featured Stories
Receive News & Ratings for First Tracks Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Tracks Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
